ForSight Robotics, a Yokneam, Israel-based pioneer in ophthalmic robotic surgery, completed a $55m Series A funding round.
The Adani Group led the funding round alongside existing investors Eclipse Ventures and Mithril Capital. A number of new investors, including Provenio Capital, Precision Capital, Reiya Ventures, the Ljungstrom family office, and other prominent private investors also joined the round.
The funding will be used to accelerate the development of the ForSight’s ORYOM platform in clinical trials.
Led by Chief Executive Officer and Co-Founder Dr. Daniel Glozman and Co-Founder and Chief Business Officer Dr. Joseph Nathan, ForSight Robotics is developing Oryom, a hybrid intraocular robotic ophthalmic platform, to advance ophthalmic surgery to treat a wide range of conditions including cataract, glaucoma, and other retinal diseases.
The platform has already been used successfully in multiple cataract procedures on an animal eye model by a number of ophthalmic surgeons.
ForSight ORYOM is being developed by leading robotic experts and prominent ophthalmic surgeons. These include Dr. Fred Moll and Mr. Rony Abovitz as part of the company’s strategic board ,and Prof. Moshe Shoham, ForSight co-founder and chief scientific officer. The company has a prestigious clinical advisory board which includes Dr. David Chang, Prof. Boris Malyugin, Dr. Elizabeth Yeu, Dr. Sam Garg, Dr. Vance Thompson and Dr. Modi Naftali.
FinSMEs
20/08/2022